Posted in Business News Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes Editor December 3, 2019 Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam folder to confirm your subscription. Original Source
